 Proactive Investors USA & Canada | AstraZeneca, Rigel Sign Potentially $100M Asthma Drug Deal Genetic Engineering News ... and an oral JAK3 inhibitor R548 for potential applications against transplant rejection and other immune disorders. Earlier-stage compounds are separately in ... AstraZeneca And Rigel Sign Worldwide License Agreement For A ... |
